# Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma

> **NCT03114683** · PHASE2 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 96 (actual)

## Conditions studied

- Relapsed/Refractory Classical Hodgkin's Lymphoma

## Interventions

- **DRUG:** PD1

## Key facts

- **NCT ID:** NCT03114683
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-30
- **Primary completion:** 2019-09-12
- **Final completion:** 2019-11-30
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2020-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03114683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03114683, "Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03114683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*